Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2008-01-01
2008-01-01
Haddad, Maher M. (Department: 1644)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S093700, C435S007100, C435S069600, C435S326000, C530S387100, C530S388100
Reexamination Certificate
active
07314615
ABSTRACT:
The present invention provides an isolated nucleic acid molecules encoding IκB kinase (IKK) catalytic subunit polypeptides, which are associated with an IKK serine protein kinase that phosphorylates a protein (IκB) that inhibits the activity of the NF-κB transcription factor, vectors comprising such nucleic acid molecules and host cells containing such vectors. In addition, the invention provides nucleotide sequences that can bind to a nucleic acid molecule of the invention, such nucleotide sequences being useful as probes or as antisense molecules. The invention also provides isolated IKK catalytic subunits, which can phosphorylate an IκB protein, and peptide portions of such IKK subunit. In addition, the invention provides anti-IKK antibodies, which specifically bind to an IKK complex or an IKK catalytic subunit, and IKK-binding fragments of such antibodies. The invention further provides methods of substantially purifying an IKK complex, methods of identifying an agent that can alter the association of an IKK complex or an IKK catalytic subunit with a second protein, and methods of identifying proteins that can interact with an IKK complex or an IKK catalytic subunit.
REFERENCES:
patent: 5264563 (1993-11-01), Huse
patent: 5270163 (1993-12-01), Gold et al.
patent: 5843721 (1998-12-01), Rothe et al.
patent: 5851812 (1998-12-01), Goeddel
patent: 5916760 (1999-06-01), Goeddel et al.
patent: 5972674 (1999-10-01), Mercurio et al.
patent: 6235512 (2001-05-01), Rothe et al.
patent: 6242253 (2001-06-01), Karin et al.
patent: 6258579 (2001-07-01), Mercurio et al.
patent: 6268194 (2001-07-01), Karin et al.
patent: 6277813 (2001-08-01), Kelly
patent: 6325989 (2001-12-01), Duke-Cohan et al.
patent: 6399344 (2002-06-01), Eriksson et al.
patent: 6448052 (2002-09-01), Yasohara et al.
patent: 6517834 (2003-02-01), Weinrich et al.
patent: WO 96/27386 (1996-09-01), None
Thompson et al. Cell. 1995. 80:573-582.
Auphan et al., “Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis,”Science270:286-90 (1995).
Ausubel et al., (eds.)Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994-1998), not supplied.
Baeuerle and Baltimore, “NF-kappa B: ten years after,”Cell87:13-20 (1996).
Baldi et al., “Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha,”J Biol Chem271:376-9 (1996).
Baldwin, “The NF-kappa B and I kappa B proteins: new discoveries and insights,”Annu Rev Immunol14:649-83 (1996).
Blondelle et al., “Soluble combinatorial libraries of organic, peptidomimetic and peptide diversities,”Trends Anal Chem14:83-92 (1992).
Borrabaeck,Antibody Engineering, second edition, New York: Oxford University Press (1995), not supplied.
Brown et al., “Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation,”Science267:1485-8 (1995).
Chen et al., “Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity,”Cell84:853-62 (1996).
Connelly and Marcu, “CHUK, a new member of the helix-loop-helix and leucine zipper families of interacting proteins, contains a serine-threonine kinase catalytic domain,”Cell Mol Biol Res41:537-49 (1995).
DiDonato et al., “Phosphorylation of I kappa B alpha precedes but is not sufficient for its dissociation from NF-kappa B,”Mol Cell Biol15:1302-11 (1995).
DiDonato et al., “Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation,”Mol Cell Biol16:1295-304 (1996).
DiDonato et al., “A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB,”Nature388:548-54 (1997).
Ecker and Crooke, “Combinatorial drug discovery: which methods will produce the greatest value?”Biotechnology(NY) 13:351-60 (1995).
Eckmann et al., “Entamoeba histolytica trophozoites induce an inflammatory cytokine response by cultured human cells through the paracrine action of cytolytically released interleukin-1 alpha,”J Clin Invest96:1269-79 (1995).
Fearon et al., “Karyoplasmic interaction selection strategy: a general strategy to detect protein-protein interactions in mammalian cells,”Proc Natl Acad Sci USA89:7958-62 (1992).
Fields and Song, “A novel genetic system to detect protein-protein interactions,”Nature340:245-6 (1989).
Flotte, “Prospects for virus-based gene therapy for cystic fibrosis,”J Bioenerg Biomembr25:37-42 (1993).
Goeddel (ed.)Meth Enzymol185 (1990), not supplied.
Gold et al., “From oligonucleotide shapes to genomic SELEX: novel biological regulatory loops,”Proc Natl Acad Sci USA94:59-64 (1997).
Hanks and Quinn, “Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members,”Methods Enzymol200:38-62 (1991).
Harlowe and Lane,Antibodies A Laboratory Manual, Cold Spring Harbor: Cold Spring Harbor Laboratory Press (1988), not supplied.
Haskill et al., “Characterization of an immediate-early gene induced in adherent monocytes that encodes IκB-like activity,”Cell65:1281-9 (1991).
Haystead et al., “Gamma-phosphate-linked ATP-sepharose for the affinity purification of protein kinases. Rapid purification to homogeneity of skeletal muscle mitogen-activated protein kinase kinase,”Eur J Biochem214:459-67 (1993).
Hermanson,Bioconjugate TechniquesSan Diego: Academic Press (1996), not supplied.
Hilyard,Protein Engineering(1992), not supplied.
Huse et al., “Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda,”Science246:1275-81 (1989).
Jellinek et al., “Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor,”Biochemistry34:11363-72 (1995).
Jolly, “Viral vector systems for gene therapy,”Cancer Gene Ther1:51-64 (1994).
Kirshenbaum et al., “Highly efficient gene transfer into adult ventricular myocytes by recombinant adenovirus,”J Clin Invest92:381-7 (1993).
Kolodziej and Young, “Epitope tagging and protein surveillance,”Methods Enzymol194:508-19 (1991).
Kumar et al., “Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B,”Proc Natl Acad Sci USA91:6288-92 (1994).
Lee et al., “Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway,”Cell88:213-22 (1997).
Liang et al., “Parallel synthesis and screening of a solid phase carbohydrate library,”Science274:1520-2 (1996).
Lin et al., “Modified RNA sequence pools for in vitro selection,”Nucleic Acids Res22:5229-34 (1994).
Liu et al., “Dissection of TNF: receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death,”Cell87:565-76 (1996).
Malinin et al., “MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1,”Nature385:540-4 (1997).
Maran et al., “Blockage of NF-κB signaling by selective ablation of an mRNA target by 2-5A antisense chimeras,”Science265:789-92 (1994).
Michael et al., “Binding-incompetent adenovirus facilitates molecular conjugate-mediated gene transfer by the receptor-mediated endocytosis pathway,”J Biol Chem268:6866-9 (1993).
Morishita et al., “Novel and effective gene transfer technique for study of vascular renin angiotensin system,”J Clin Invest91:2580-5 (1993).
Pagratis et al., “Potent 2′-amino-, and 2′-fluoro-2′-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor,” Nat Biotechnol 15:68-73 (1997).
Regnier et al., “Identification and characterization of an IkappaB kinase,”Cell90:373-83 (1997).
DiDonato Joseph A.
Hayakawa Makio
Karin Michael
Rothwarf David M.
Zandi Ebrahim
Crowder Chun
Haddad Maher M.
Medlen & Carroll LLP
The Regents of the University of California
LandOfFree
IκB Kinase-β (IKKβ) binding antibodies and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IκB Kinase-β (IKKβ) binding antibodies and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IκB Kinase-β (IKKβ) binding antibodies and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2806474